On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
US regulators have granted the world’s first approval for Daiichi Sankyo/AstraZeneca’s HER2-targeting antibody drug conjugate (ADC) trastuzumab deruxtecan, which now carries the brand name of Enhertu, for the treatment of certain patients with advanced breast cancer. The green light on…
To read the full story
Related Article
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
BUSINESS
- Kolon Ordered Payment to Mitsubishi Tanabe over Cell Therapy License Deal
January 15, 2021
- Genmab Set for Stand-Alone Drug Development, Biz in Japan
January 15, 2021
- Kaken to Codevelop Novel Multi-Specific Antibody with Swiss Biotech
January 15, 2021
- Daiichi Sankyo’s DMD Therapy Shows Efficacy in Several Patients in PI/II
January 14, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…